carbamazepine · Lundbeck Pharms Llc · NDA 206030
Carnexiv
Earliest generic entry, as listed
31 Jan 2040
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11529357.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11529357 | product | 31 Jan 2040 |
| US 9493582 | product | 27 Feb 2033 |
| US 7635773 | product | 13 Mar 2029 |
| US 8410077 | product | 13 Mar 2029 |
| US 9750822 | product | 13 Mar 2029 |
| US 9629797 | use U-2006 | 10 Nov 2028 |
| US 9629797 | use U-2004 | 10 Nov 2028 |
| US 9629797 | use U-2005 | 10 Nov 2028 |
| US 9770407 | product | 10 Nov 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206030 · 001 · RLD · discontinued | solution, intravenous | 200MG/20ML (10MG/ML) | 31 Jan 2040 |